These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Oncolytic adenovirus armed with shRNA targeting MYCN gene inhibits neuroblastoma cell proliferation and in vivo xenograft tumor growth. Li Y; Zhang B; Zhang H; Zhu X; Feng D; Zhang D; Zhuo B; Li L; Zheng J J Cancer Res Clin Oncol; 2013 Jun; 139(6):933-41. PubMed ID: 23443256 [TBL] [Abstract][Full Text] [Related]
3. Anti-cancer effect of oncolytic adenovirus-armed shRNA targeting MYCN gene on doxorubicin-resistant neuroblastoma cells. Li Y; Zhuo B; Yin Y; Han T; Li S; Li Z; Wang J Biochem Biophys Res Commun; 2017 Sep; 491(1):134-139. PubMed ID: 28711493 [TBL] [Abstract][Full Text] [Related]
4. Didymin induces apoptosis by inhibiting N-Myc and upregulating RKIP in neuroblastoma. Singhal J; Nagaprashantha LD; Vatsyayan R; Ashutosh ; Awasthi S; Singhal SS Cancer Prev Res (Phila); 2012 Mar; 5(3):473-83. PubMed ID: 22174364 [TBL] [Abstract][Full Text] [Related]
5. MYCN-directed centrosome amplification requires MDM2-mediated suppression of p53 activity in neuroblastoma cells. Slack AD; Chen Z; Ludwig AD; Hicks J; Shohet JM Cancer Res; 2007 Mar; 67(6):2448-55. PubMed ID: 17363562 [TBL] [Abstract][Full Text] [Related]
6. MYCN sensitizes human neuroblastoma to apoptosis by HIPK2 activation through a DNA damage response. Petroni M; Veschi V; Prodosmo A; Rinaldo C; Massimi I; Carbonari M; Dominici C; McDowell HP; Rinaldi C; Screpanti I; Frati L; Bartolazzi A; Gulino A; Soddu S; Giannini G Mol Cancer Res; 2011 Jan; 9(1):67-77. PubMed ID: 21173028 [TBL] [Abstract][Full Text] [Related]
7. Stable knockdown of MYCN by lentivirus-based RNAi inhibits human neuroblastoma cells growth in vitro and in vivo. Jiang R; Xue S; Jin Z Biochem Biophys Res Commun; 2011 Jul; 410(2):364-70. PubMed ID: 21683062 [TBL] [Abstract][Full Text] [Related]
8. Oncolytic adenovirus-mediated shRNA against Apollon inhibits tumor cell growth and enhances antitumor effect of 5-fluorouracil. Chu L; Gu J; Sun L; Qian Q; Qian C; Liu X Gene Ther; 2008 Apr; 15(7):484-94. PubMed ID: 18239605 [TBL] [Abstract][Full Text] [Related]
9. Biological effects of induced MYCN hyper-expression in MYCN-amplified neuroblastomas. Torres J; Regan PL; Edo R; Leonhardt P; Jeng EI; Rappaport EF; Ikegaki N; Tang XX Int J Oncol; 2010 Oct; 37(4):983-91. PubMed ID: 20811720 [TBL] [Abstract][Full Text] [Related]
10. p53 is a direct transcriptional target of MYCN in neuroblastoma. Chen L; Iraci N; Gherardi S; Gamble LD; Wood KM; Perini G; Lunec J; Tweddle DA Cancer Res; 2010 Feb; 70(4):1377-88. PubMed ID: 20145147 [TBL] [Abstract][Full Text] [Related]
11. Cyclin-Dependent Kinase Inhibitor AT7519 as a Potential Drug for MYCN-Dependent Neuroblastoma. Dolman ME; Poon E; Ebus ME; den Hartog IJ; van Noesel CJ; Jamin Y; Hallsworth A; Robinson SP; Petrie K; Sparidans RW; Kok RJ; Versteeg R; Caron HN; Chesler L; Molenaar JJ Clin Cancer Res; 2015 Nov; 21(22):5100-9. PubMed ID: 26202950 [TBL] [Abstract][Full Text] [Related]
12. MYCN concurrence with SAHA-induced cell death in human neuroblastoma cells. Cortés C; Kozma SC; Tauler A; Ambrosio S Cell Oncol (Dordr); 2015 Oct; 38(5):341-52. PubMed ID: 26306783 [TBL] [Abstract][Full Text] [Related]
13. Crosstalk between MYCN and MDM2-p53 signal pathways regulates tumor cell growth and apoptosis in neuroblastoma. He J; Gu L; Zhang H; Zhou M Cell Cycle; 2011 Sep; 10(17):2994-3002. PubMed ID: 21862876 [TBL] [Abstract][Full Text] [Related]
14. Inhibitors of mammalian target of rapamycin downregulate MYCN protein expression and inhibit neuroblastoma growth in vitro and in vivo. Johnsen JI; Segerström L; Orrego A; Elfman L; Henriksson M; Kågedal B; Eksborg S; Sveinbjörnsson B; Kogner P Oncogene; 2008 May; 27(20):2910-22. PubMed ID: 18026138 [TBL] [Abstract][Full Text] [Related]
15. Transcriptional repression of SKP2 is impaired in MYCN-amplified neuroblastoma. Muth D; Ghazaryan S; Eckerle I; Beckett E; Pöhler C; Batzler J; Beisel C; Gogolin S; Fischer M; Henrich KO; Ehemann V; Gillespie P; Schwab M; Westermann F Cancer Res; 2010 May; 70(9):3791-802. PubMed ID: 20424123 [TBL] [Abstract][Full Text] [Related]
16. MYCN silencing induces differentiation and apoptosis in human neuroblastoma cells. Kang JH; Rychahou PG; Ishola TA; Qiao J; Evers BM; Chung DH Biochem Biophys Res Commun; 2006 Dec; 351(1):192-7. PubMed ID: 17055458 [TBL] [Abstract][Full Text] [Related]
17. Inhibition of mir-21, which is up-regulated during MYCN knockdown-mediated differentiation, does not prevent differentiation of neuroblastoma cells. Buechner J; Henriksen JR; Haug BH; Tømte E; Flaegstad T; Einvik C Differentiation; 2011 Jan; 81(1):25-34. PubMed ID: 20980091 [TBL] [Abstract][Full Text] [Related]
18. Next-generation RNA sequencing reveals differential expression of MYCN target genes and suggests the mTOR pathway as a promising therapy target in MYCN-amplified neuroblastoma. Schramm A; Köster J; Marschall T; Martin M; Schwermer M; Fielitz K; Büchel G; Barann M; Esser D; Rosenstiel P; Rahmann S; Eggert A; Schulte JH Int J Cancer; 2013 Feb; 132(3):E106-15. PubMed ID: 22907398 [TBL] [Abstract][Full Text] [Related]
19. Inactivation of CDK2 is synthetically lethal to MYCN over-expressing cancer cells. Molenaar JJ; Ebus ME; Geerts D; Koster J; Lamers F; Valentijn LJ; Westerhout EM; Versteeg R; Caron HN Proc Natl Acad Sci U S A; 2009 Aug; 106(31):12968-73. PubMed ID: 19525400 [TBL] [Abstract][Full Text] [Related]
20. MYCN and MYC regulate tumor proliferation and tumorigenesis directly through BMI1 in human neuroblastomas. Huang R; Cheung NK; Vider J; Cheung IY; Gerald WL; Tickoo SK; Holland EC; Blasberg RG FASEB J; 2011 Dec; 25(12):4138-49. PubMed ID: 21856782 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]